This trial tests ponatinib hydrochloride as second line therapy for CML patients who didn't respond to initial treatment with imatinib mesylate, dasatinib, or nilotinib, or can't tolerate those treatments. Ponatinib hydrochloride may work by blocking a protein needed for cell growth.
2 Primary · 4 Secondary · Reporting Duration: Up to 5 years
Experimental Treatment
50 Total Participants · 1 Treatment Group
Primary Treatment: Ponatinib Hydrochloride · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: